Hurdles Remain in VC Funding Environment for MDx Firms | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – A rapidly changing regulatory environment, slow adoption by clinicians, and the soft economy continue to be barriers to venture capital investments into the molecular diagnostics space, according to some VC investors and officials at MDx firms, with one venture capitalist calling the current environment one of the worst he's seen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.